Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
← catalyst calendarSponsored by Imunon (industry) · IMNN — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Na · None · Prevention
Enrollment
24actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-04 | actual | When the study began enrolling |
| Primary completion | 2025-03-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-07 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- SARS CoV 2 Infection
Intervention
- Biological: IMNN-101
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with local and systemic reactogenicity adverse events and all adverse events
measured 1 month
Number of participants with geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain.
measured 12 months
Permalink · IMNN's whole pipeline · Catalyst calendar · Every registered study · What changed